Email this article SIDE EFFECTS OF TWO REGIMENS OF TRIPLE-COMPONENT CHEMOTHERAPY (CAPECITABINE, OXALIPLATIN AND IRINOTECAN) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
- Authors: Semenov N.N1, Meshcheryakov A.A1
-
Affiliations:
- N. N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences
- Issue: Vol 19, No 3 (2014)
- Pages: 29-31
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40058
- DOI: https://doi.org/10.17816/onco40058
- ID: 40058
Cite item
Full Text
Abstract
Last ESMO and NCCN recommendations for the treatment of metastatic colorectal cancer include the use of a triple-component chemotherapy. A study of two modes with the inclusion of irinotecan dose of 120 mg/m2 every 2 weeks, oxaliplatin 85 mg/m2 every 2 weeks, the dose of capecitabine 1600 mg/m2/day in 1-7 days with a 1- week break or 1600 mg/m 2 / day in days 1-14 with a 2-week break. Both modes showed satisfactory tolerance without significant gastrointestinal and hematological toxicity. Plan to further study the development of ternary diagrams for the application of the algorithm implementation in a wide oncological practice.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
N. N Semenov
N. N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences
Email: niksemenov1969@yandex.ru
д-р мед. наук, ст. научн. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Moscow, Russian Federation
A. A Meshcheryakov
N. N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences115478, Moscow, Russian Federation
References
- Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 2012; 23: 2479-516.
- Мещеряков А.А. Дифференцированное решение о назначении первой линии химиотерапии диссеминированного рака толстой кишки. Эффективная фармакотерапия. 2011; 3: 28-30.
- Bajetta E., Celio L., Ferrario E., Di Bartolomeo M., Denaro A., Dotti K. et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2007; 18: 1810-6.
- Fornaro L., Masi G., Bursi S., Loupakis F., Vasile E., Antonuzzo A. et al. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemother. Pharmacol. 2009; 63 (5): 965-9.
- Vasile E., Masi G., Fornaro L., Cupini S., Loupakis F., Bursi S. et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer. 2009; 100: 1720-4.
- Von Moos R., Roth A., Ruhstaller T., Widmer L., Uhlmann C., Cathomas R. et al. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010; 33 (6): 295-9.
- Zarate R., Rodriguez J., Bandres E., Patino-Garcia A., Ponz-Sarvise M., Viudez A. et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br. J. Cancer. 2010; 102: 987-94.
